Vertex Pharmaceuticals Incorporated
Clinical trials sponsored by Vertex Pharmaceuticals Incorporated, explained in plain language.
Biopharmaceutical company focused on cystic fibrosis and other serious diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could this Stem-Cell infusion end insulin shots for diabetics with kidney transplants? Results expected Sep 2026 (estimated)
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug Results expected Oct 2026 (estimated)
- New triple therapy shows promise for cystic fibrosis in Long-Term trial Results expected Oct 2026 (estimated)
- New CF drug candidate VX-581 begins first human safety tests Results expected Nov 2026 (estimated)
- Gene study aims to unlock secrets of kidney disease Results expected Dec 2026 (estimated)